<DOC>
	<DOCNO>NCT00315276</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety modafinil administer daily 9 week dose 255 , 340 , 425 , 510 mg treatment adult ADHD .</brief_summary>
	<brief_title>Dose-Finding Study Evaluate Efficacy Safety Modafinil Treatment Adults With ADHD</brief_title>
	<detailed_description>The primary objective study determine whether modafinil 255 , 340 , 425 , 510 mg'day effective placebo alleviate symptom Attention-Deficit/Hyperactivity Disorder ( ADHD ) adult determine change baseline total score investigator-completed Adult ADHD Investigator Symptoms Rating Scale ( AISRS ) endpoint ( last post-baseline observation [ week 9 early termination ] ) .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Written inform consent obtain . The patient 18 65 year age ( inclusive ) screen visit English speaking . At screen ( washout , require ) patient meet full Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion ADHD ( combine type , predominantly inattentive subtype , predominantly hyperactivityimpulsive subtype ) , symptoms present age 7 symptom persistent least last 6 month , accord psychiatric/clinical evaluation use adult ADHD Clinical Diagnosis Scale , Version 1.2 ( ACDS ) . The patient Hamilton Anxiety Scale ( HAMA ) Hamilton Depression Scale ( HAMD ) score less 15 . The patient AISRS total score great 24 screen baseline visit , difference total score screen visit baseline visit le 25 % . The patient Clinical Global Impression Severity Illness ( CGIS ) rating ADHD least 4 baseline visit . Women childbearing potential ( surgically sterile 2 year postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study . Acceptable method contraception include barrier method spermicide , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method , intrauterine device [ IUD ] . The patient must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation specify protocol . The patient history current diagnosis schizophrenia , bipolar psychotic disorder , clinical assessment suicide risk . The patient current psychiatric comorbidity , include limited depression mood disorder anxiety disorder , require pharmacotherapy . Comorbidities assess use select module ( ie , psychosis , substance abuse , mood disorder , anxiety disorder ) Structured Clinical Interview DSMIVTR ( SCID ) . The patient current diagnosis clinically significant sleep disorder . The patient intellectually challenge , determine investigator . The patient satisfy current ADHD medication unacceptable medication side effect . The patient previously use modafinil . The patient use prescription medication ADHD psychoactive property ( eg , amphetamine , dextroamphetamine , methylphenidate , pemoline , atomoxetine ) baseline visit . The patient drug alcohol abuse dependence within last 6 month . The patient use monoamine oxidase ( MAO ) inhibitor selective serotonin reuptake inhibitor ( SSRIs ) within 2 week baseline visit . The patient use investigational drug within 1 month baseline visit . The patient pregnant lactating . ( Any patient become pregnant study withdrawn study ) . The patient clinically significant uncontrolled medical condition ( treat untreated ) . The patient clinically significant deviation normal physical examination . The patient disorder may interfere drug absorption , distribution , metabolism , excretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>ADHD</keyword>
</DOC>